Issues to debate n the Women's Health Initiative (WHI) study. Hormone replacement therapy: An epidemiological dilemma?

Human Reproduction

Volumn 18, Issue 10, 2003, Pages 1992-1999

  Machens, Kathrin ^a   Schmidt Gollwitzer, K ^a,b  

^a BAYER PHARMA AG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Disease outcomes; Epidemiology; HERS HERS II; Hormone replacement therapy; WHI

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEX HORMONE; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; CLINICAL TRIAL; COLORECTAL CARCINOMA; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEMALE; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MATERNAL CARE; MEDICAL RESEARCH; MENOPAUSE RELATED DISORDER; OUTCOMES RESEARCH; POPULATION RESEARCH; POSTMENOPAUSE; PUBLISHING; REVIEW; STATISTICAL ANALYSIS; STROKE; VAGINA BLEEDING; BIOMETRY; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COMBINATION; ESTROGEN THERAPY; INFORMATION PROCESSING; METHODOLOGY; MORTALITY; NEOPLASM; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RISK;

BIOMETRY; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DATA COLLECTION; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); HIP FRACTURES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK;

EID: 0142126274     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deg406     Document Type: Review

References (23)

1. Bock, J. (1998) Bestimmung des Stichprobenumfangs für Biologische Experimente und Kontrollierte Klinische Studien. R. Oldenbourg, München, Germany, pp. 96-98.
2. Clarkson, T.B. (2002) The new conundrum: Do estrogens have any cardiovascular benefits? Int. J. Fertil., 47, 61-68.
3. Clarkson, T.B., Anthony, M.S., Mikkola, T.S. and St. Clair, R.W. (2002) Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke, 33, 2700-2703.
4. Concato, J., Feinstein, A.R. and Holford, T.R. (1993) The risk of determining risk with multivariable models. Ann. Intern. Med., 118, 201-210.
5. De Kleijn, M.J., Van Der Schouw, Y.T., Verbeek, A.L., Peeters, P.H., Banga, J.D. and Van Der Graaf, Y. (2002) Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am. J. Epidemiol., 155, 339-345.
6. Von Fournier, D., Weber, E., Hoeffken, W., Bauer, M., Kubli, M. and Barth, V. (1080) Growth rate of 147 mammary carcinomas. Cancer, 45, 2198-2207.
7. Gambacciani, M., Rosano, G.M.C., Monteleone, P. and Genazzani, A.R. (2002) Clinical relevance of the HERS trial. Lancet, 360, 641.
8. Genazzani, A.R. (2002a) Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation, 105, e71.
9. Genazzani, A.R. (2002b) A personal initiative for women's health: To challenge the Women's Health Initiative. Gynecol. Endocrinol., 16, 255-257.
10. Grady, D., Rubin, S.M., Petitti, D.B., Fox, C.S., Black, D., Ettinger, B., Ernster, V.L. and Cummings, S.R. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med., 117, 1016-1037.
11. Grady, D., Herrington, D., Bittner, V. et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy, Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J. Am. Med. Assoc., 288, 49-57.
12. Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E. and Hennekens, C.H. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 335, 453-461.
13. Grodstein, F., Manson, J.E. and Stampfer, M.J. (2001) Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann. Intern. Med., 135, 1351-1358.
14. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. and Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc., 280, 605-613.
15. Hulley, S., Furberg, C., Barrett-Connor, E. et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy, Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J. Am. Med. Assoc., 288, 58-66.
16. Johnson, S.R. (1998) Menopause and hormone replacement therapy. Med. Clin. North. Am., 82, 297-320.
17. Nanda, K., Bastian, L.A., Hasselblad, V. and Simel, D.L. (1999) Hormone replacement therapy and the risk of colorectal cancer: A meta-analysis. Obstet. Gynecol., 93, 880-888.
18. Nelson, H.D., Humphrey, L.L., Nygren, P., Teutsch, S.M. and Allan, J.D. (2002) Postmenopausal hormone replacement therapy. J. Am. Med. Assoc., 288, 872-881.
19. Nevitt, M.C., Cummings, S.R., Lane, N.E., Hochberg, M.C., Scott, J.C., Pressman, A.R., Genant, H.K. and Cauley, J.A. (1996) Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Ann. Intern. Med., 156, 2073-2080.
20. Panidis, D. and Stergiopoulos, K. (1998) Estrogens and Alzheimer disease. Hellen. Med., 64, 335-342.
21. Rossouw, J.E., Finnegan, L.P., Harlan, W.R., Pinn, V.W., Clifford, C. and McGowan, J.A. (1995) The evolution of the women's health initiative: Perspectives from the NIH. J. Am. Med. Assoc., 50, 50-55.
22. WHI Study Group (1998) Design of the Women's Health Initiative clinical trial and observational study. Controlled Clin. Trials, 19, 61-109.
23. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principle results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc., 288, 321-333.